Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Tuesday announced positive topline results from the Phase 3 VERITAC-2 study.
The study is designed to evaluate the companies' vepdegestrant compared to AstraZeneca's fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
The trial met its primary goal in the estrogen receptor 1-mutant (ESR1m) population showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. However, in the intent-to-treat (ITT) population, the study did not reach statistical significance in improvement in PFS.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.